FINWIRES · TerminalLIVE
FINWIRES

Lennar Shares Rise After Berkshire Hathaway Discloses Share Purchases

By

Lennar (LEN) shares rose nearly 6% in Tuesday trading after Berkshire Hathaway (BRK.A, BRK.B) disclosed purchases of the homebuilder's stock in a Form 4 filing with the SEC.

Berkshire subsidiaries bought roughly 2.67 million class A shares and about 75,021 class B shares between Sept. 17 and Sept. 21, in transactions valued at a combined $212.4 million, according to the filing.

Class A purchases were made at weighted-average prices ranging from $76.39 to $79.41 per share, while class B shares were bought at weighted-average prices between $74.80 and $78.38.

Following the transactions, Berkshire's subsidiaries beneficially own 23,719,109 class A shares and 528,217 class B shares of Lennar.

Price: $82.65, Change: $+4.57, Percent Change: +5.85%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA